European Commission approves Astellas’ drug for expanded prostate cancer Treatment

On April 24, Astellas Pharma Inc. revealed that XTANDI enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) treatment in the European Union (EU).